<DOC>
	<DOC>NCT02665832</DOC>
	<brief_summary>The purpose of this study is to compare the safety and pharmacokinetic characteristics of combination of amlodipine, olmesartan and rosuvastatin and DWJ1351 in healthy male volunteers</brief_summary>
	<brief_title>Study of DWJ1351 in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Healthy adult male subjects aged 19 to 50 years Subjects whose body weight ≥ 55 kg and Body Mass Index(BMI) ≥ 18.0 kg/m2 and ≤ 27.0 kg/m2 Subject who was judged to be healthy and suitable for the participation by the investigator based on screening test results Subject who provided written informed consent to participate in this study Subject who had a severe allergy or allergic reactions to the amlodipine, olmesartan, rosuvastatin or related drugs Subject with sign or symptoms or previously diagnosed disease of liver, kidney, neurology, respiratory, endocrinology, hematology, cardiovascular, digestive system, reproductive system, neurology, psychology, ophthalmic and skin disease Subjects who had a serious clinical illness that can impact fate of drugs absorption Subject who shows vital signs with the number of systolic blood pressure of ≥150 mmHg or ≤100 mmHg, and the number of diastolic blood pressure of ≥100mmHg or ≤66mmHg Subject who have experienced drug abuse Subject who donates his blood (whole blood donation within last 2 months or plasma donation within last 1 month) Subject who has taken other clinical or licensed medication from another clinical trial within an 3month period prior to the first administration of the study medication</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>